Gilead Files Once-Daily Integrase Inhibitor Elvitegravir With FDA

Part of the Quad combination product, stand-alone elvitegravir could open up the integrase inhibitor market. In a study supporting the single-agent NDA, once-daily elvitegravir proved comparable to Merck’s twice-daily blockbuster Isentress, the only commercially available integrase inhibitor.

Gilead Sciences Inc.’s submission of its HIV therapy elvitegravir to FDA, announced late June 27, could mean the beginning of competition in the integrase inhibitor field – and offer the first once-daily option.

More from Archive

More from Pink Sheet